Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study

Article ID	Journal	Published Year	Pages	File Type
5657202	Clinical Gastroenterology and Hepatology	2017	35 Pages	PDF

Abstract

In a phase 2 study, we found no difference between a THC tablet and a placebo tablet in reducing pain measures in patients with chronic abdominal pain. THC, administered 3 times daily, was safe and well-tolerated during a 50-day to 52-day treatment period. ClinicalTrials.gov number: NCT01562483 and NCT01551511.

Keywords

time to reach maximum plasma concentration Cmax SF-36 RCT VAS THC tmax PGIC PSP NRS AUC Δ-9-tetrahydrocannabinol Randomized controlled trial standard deviation Patient Global Impression of Change maximum plasma concentration chronic pain Postsurgical pain TID three times a day Apple adverse event Pharmacokinetics confidence interval Marijuana visual analogue scale numeric rating scale area under the curve chronic pancreatitis

Related Topics

Health Sciences Medicine and Dentistry Gastroenterology

Preview

Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study

Authors

Marjan de Vries, Dagmar C.M. van Rijckevorsel, Kris C.P. Vissers, Oliver H.G. Wilder-Smith, Harry van Goor, Pain and Nociception Neuroscience Research Group Pain and Nociception Neuroscience Research Group,